What is B. Riley’s Estimate for Immunic Q1 Earnings?

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at B. Riley boosted their Q1 2025 earnings per share (EPS) estimates for shares of Immunic in a research note issued to investors on Wednesday, April 16th. B. Riley analyst W. Wood now expects that the company will post earnings of ($0.26) per share for the quarter, up from their prior forecast of ($0.29). B. Riley has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. B. Riley also issued estimates for Immunic’s Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.75) EPS.

Other analysts also recently issued research reports about the stock. D. Boral Capital reissued a “buy” rating and issued a $17.00 price target on shares of Immunic in a research report on Thursday, April 10th. William Blair initiated coverage on shares of Immunic in a research report on Tuesday, March 25th. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Immunic in a report on Tuesday. Finally, StockNews.com downgraded Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $13.20.

Immunic Stock Performance

Shares of Immunic stock opened at $0.98 on Friday. Immunic has a 52 week low of $0.83 and a 52 week high of $2.11. The stock has a 50 day moving average price of $1.08 and a two-hundred day moving average price of $1.14. The stock has a market capitalization of $88.35 million, a PE ratio of -0.80 and a beta of 1.91.

Institutional Investors Weigh In On Immunic

A number of institutional investors have recently added to or reduced their stakes in IMUX. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after buying an additional 38,553 shares during the last quarter. HB Wealth Management LLC bought a new stake in Immunic during the fourth quarter worth $81,000. State Street Corp boosted its position in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares during the last quarter. Virtu Financial LLC bought a new position in Immunic in the 3rd quarter valued at $50,000. Finally, Millennium Management LLC increased its position in shares of Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the last quarter. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.